GlycoMimetics to Report Fourth Quarter and Year-End 2017 Financial Results on March 6, 2018
Discussion to focus on Phase 3 development plans for GMI-1271 in AML
The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 1453008. A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 1453008.
About GMI-1271
About
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics' most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and a Phase 3
clinical trial being conducted by its strategic collaborator, Pfizer is
expected to read out in the second half of
2018. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an
E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a
potential treatment for AML, and the Company plans to initiate a Phase 3
trial in AML in 2018. Clinicians are also currently evaluating GMI-1271
in a Phase 1 clinical trial for the treatment of multiple myeloma. The
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1271, including the expected timing of
completion of clinical trials and the presentation of clinical data.
Actual results may differ materially from those in these forward-looking
statements. For a further description of the risks associated with these
statements, as well as other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20180227005410/en/
Source:
GlycoMimetics, Inc.
Investor Contact:
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Media
Contact:
Jamie Lacey-Moreira, 410-299-3310
jamielacey@presscommpr.com